Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027911 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma
A Phase 1 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00027911: Clinical Trial Phase 1 study, sponsored by Columbia University.
NCT00027911 is a Phase 1 study that was terminated before completion, run by Columbia University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027911, a Phase 1 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may be effective in treating soft tissue sarcoma. PURPOSE: Phase I trial to study the effectiveness of combining vaccine therapy with sargramostim in treating patients who have stage II, stage III, or stage IV soft tissue sarcoma.
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL NY-ESO-1 peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-04 |
| Est. Completion | 2005-06 |
| Phase | Phase 1 |
Why NCT00027911 stopped before completion
NCT00027911 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which sargramostim is the first listed.
NCT00027911 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00027911 about?
NCT00027911 is a clinical study titled "Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may be effective in treating soft tissue sarco...
What is the current status of trial NCT00027911?
This trial is currently terminated. It is a Phase 1 study. The study started on 2001-04. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00027911?
The interventions under investigation include: sargramostim (BIOLOGICAL), NY-ESO-1 peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00027911?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia